Recruiting | Phase III
A Randomized Phase III study of Ibrutinib Plus Obinutuzumab versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 years of age) with Chronic Lymphocytic Leukemia (CLL)
To compare the usual treatment alone (Ibrutinib plus Obinutuzumab) to using Venetoclax plus the usual treatment. The addition of Venetoclax to the usual treatment could prevent chronic lymphocytic leukemia from returning.
- Group 1: Ibrutinib plus Obinutuzumab
- Group 2: Ibrutinib plus Obinutuzumab plus Venetoclax (study drug)
Key Participation Requirements:
Male or Female
≥ 70 years
Chronic Lymphocytic Leukemia
Confirmed Chronic Lymphocytic Leukemia diagnosis.
Central FISH blood submission.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.